SENSORION overview

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Pr. Natalie Loundon, pediatric ENT Surgeon, Director of the Center for Research in Pediatric Audiology, Necker Enfants Malades Hospital, AP-HP, in Paris, France, will make an oral presentation at the annual meeting of the American Society of Pediatric Otolaryngology...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France. The prior notice of meeting...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that it will host a symposium at the 4 th International Conference on Inner Ear Therapies, ISIET, in Marrakech, Morocco, on April 26, 2025, from 11.30 am to 12.15 pm CET. The symposium, entitled: “ Hearing Loss Innovation: Expanding Frontiers in Protection & Restoration ”,...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion’s independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced it will host a webconference for its retail shareholders on April 7, 2025, following its Full-Year 2024 release. The webconference will be held in French. Sensorion’s Chief Executive Officer, Nawal Ouzren, and management team, will host a webconference dedicated to its...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces its participation at the Van Lanschot Kempen conference , to be held in Amsterdam, Netherlands, on April 2-3, 2025. This conference is an important meeting place for life sciences companies and institutional investors. Sensorion's management team will be present for...

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2024 results, provided a corporate update, and announced the availability of the full-year report. “This past year has been an exceptional period of progress on clinical and corporate development fronts,” commented Nawal Ouzren, Chief Executive Officer of...